Abstract: Disclosed are methods of preparing hematopoietic stem cells and progenitor cells (HSPCs) for transplant into a subject and to methods of using the treated cells. More particularly, methods of the invention comprise treating HSPCs ex vivo with an effective amount of a GABBR1 agonist and administering the treated HSPCs to the subject.

Abstract: The preset invention relates to a novel super-enhancer-bound Ash2l/OSN complex that can drive enhance activation, govern pluripotency network and sternness circuitry, and a reprogramming system or method through the regulation of this super-enhancer, Ash2l, to modulate pluripotency and cell fates. Ash2l directly binds to super-enhancers of several stemness genes to regulate pluripotency and self-renewal in pluripotent stem cells. Ash2l recruits Oct4/Sox2/Nanog (OSN) to form Ash2l/OSN complex at the super-enhancers of Jarid2, Nanog, Sox2, and Oct4, and further drives enhancer activation, upregulation of stemness genes, and maintains the pluripotent circuitry. Ash2l knockdown abrogates the OSN recruitment to all super-enhancers and further hinders the enhancer activation.

Abstract: Described are devices and associated methods of producing extracellular matrix (ECM) sheet devices with strengthened mechanical properties due to the selective retention of muscle tissue layers during processing.

Abstract: The present invention relates to the field of in vitro 3D modeling of neural tissues, particularly of the brain. There is the need of developing cell culture models of neural tissue that reflect physiological aspects of neural tissue. The present invention provides methods of producing bioengineered neuronal organoids (BENOs) which form functional neuronal networks. The present invention also relates to uses and applications of the produced BENOs, e.g., in the fields of drug screening and personalized medicine.

Abstract: The invention discloses a method for constructing functional exosomes capable of efficiently loading specific miRNA. In order to enable the exosome to carry miRNA with specific regulation function more efficiently so as to play a role in targeted regulation more accurately and efficiently, MS2 phage capsid protein is utilized to edit and construct a capture element of a specific miRNA molecule, and placenta mesenchymal stem cells are reprogrammed to enable the secreted exosome to efficiently load a target miRNA molecule, so that the target miRNA molecule is delivered to tissue cells to play a role in effective regulation, and therefore a new strategy is provided for realizing specific precise treatment in the future.

Abstract: Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclose describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons.

Abstract: The present invention provides genetically modified non-human animals which are deficient in at least one or more types of CD3 genes selected from the group consisting of endogenous CD3?, CD3?, and CD3? in its genome and functionally express at least one or more types of human CD3 genes selected from the group consisting of human CD3?, CD3?, and CD3?. In the genetically modified non-human animals of the present invention, mature T cell differentiation and production can take place, and immunocompetent cells including T cells can exert their functions. The genetically modified non-human animals of the present invention enable efficient evaluation and screening in the development of therapeutic agents and therapeutic methods that use human CD3-mediated targeted drugs.